<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341158</url>
  </required_header>
  <id_info>
    <org_study_id>5021000</org_study_id>
    <nct_id>NCT01341158</nct_id>
  </id_info>
  <brief_title>NAM-Trial: Multiferon in Malignant Melanoma</brief_title>
  <official_title>Neoadjuvant Treatment of Locoregional Metastases in Malignant Melanoma (AJCC Stage IIIB/C) With Multiferon: a Phase IIa DeCOG Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current clinical trial shall clarify the efficacy, safety and biologic effects of&#xD;
      neoadjuvant treatment with natural interferon-α (Multiferon) in patients with locoregional&#xD;
      metastases of melanoma in stage IIIB/C.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open label, multicenter phase IIa clinical trial which is designed as a pilot&#xD;
      project in order to establish the efficacy and tolerability of Multiferon as a neoadjuvant&#xD;
      treatment of locoregional metastases. Patients will be treated subsequently in cohorts&#xD;
      characterized by different doses (3 - 9 - 18 MIU) to analyze dosage dependent effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
    <description>Overall response rate (clinical and radiological) after 4 weeks of treatment (CR + PR) according to immune-related response criteria (irRC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
    <description>Disease control rate (CR + PR +SD) according to irRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of histopathological complete responses</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
    <description>Rate of histopathological complete responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
    <description>Assessment of numbers of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in gene expression in metastatic tissue before/after treatment</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose dependency of effects</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of serum markers and PBMC subsets before/after treatment (optional translational side studies)</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Locoregional Metastases in Malignant Melanoma Stages IIIB/C</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human interferon-α</intervention_name>
    <description>Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>Multiferon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven cutaneous melanoma&#xD;
&#xD;
          2. Clinical stage IIIB or IIIC (AJCC 2010)&#xD;
&#xD;
          3. ≥ 18 years of age&#xD;
&#xD;
          4. Presence of at least two metastases, not more than 10 metastases, and completely&#xD;
             resectable&#xD;
&#xD;
          5. Measurable disease (at least one lesion that can be accurately measured in two&#xD;
             perpendicular diameters, with both dimensions at least 10 mm x 10 mm for spiral CT and&#xD;
             5 mm x 5 mm for locoregional metastases assessed by ultrasound or digital photography)&#xD;
&#xD;
          6. ECOG performance status of 0/1&#xD;
&#xD;
          7. Patients with previous adjuvant recombinant interferon-α treatment of any dose are&#xD;
             eligible if (i) treatment was stopped at least 1 month before start of treatment and&#xD;
             (ii) no progression occurred during interferon-α treatment.&#xD;
&#xD;
          8. No childbearing potential or negative pregnancy test within 14 days before inclusion&#xD;
             in women with child bearing potential Women with childbearing potential must be using&#xD;
             an effective method of contraception (Pearl-Index &lt; 1, e.g. oral contraceptives, other&#xD;
             hormonal contraceptives [vaginal products, skin patches, or implanted or injectable&#xD;
             products], or mechanical products such as an intrauterine device or barrier methods&#xD;
             [diaphragm, spermicides]) throughout the study and for up to 3 months after the last&#xD;
             dose of investigational product, in such a manner that the risk of pregnancy is&#xD;
             minimized.&#xD;
&#xD;
             No men of fathering potential or men of fathering potential must be using an effective&#xD;
             method of contraception to avoid conception throughout the study and for up to 3&#xD;
             months after the last dose of investigational product, in such a manner that the risk&#xD;
             of pregnancy is minimized.&#xD;
&#xD;
          9. Signed and dated informed consent informed consent before the start of specific&#xD;
             protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mucous membrane or ocular melanoma&#xD;
&#xD;
          2. Any evidence of distant metastasis (e.g. whole body CT-scan including brain scan&#xD;
             within 4 weeks before inclusion)&#xD;
&#xD;
          3. Patients with severe cardiac disease (e.g. NYHA Functional Class III or IV, myocardial&#xD;
             infarction within 6 months before inclusion, ventricular tachyarrhythmia requiring&#xD;
             ongoing treatment, unstable angina pectoris).&#xD;
&#xD;
          4. ALAT or ASAT &gt; 2 x ULN&#xD;
&#xD;
          5. Total bilirubin &gt; 2 x ULN&#xD;
&#xD;
          6. Creatinine &gt; 2 x ULN&#xD;
&#xD;
          7. Evidence or history of depression. If this condition can not be ruled out, the patient&#xD;
             should be transferred to a psychiatrist for consultation and further assessment before&#xD;
             inclusion.&#xD;
&#xD;
          8. Patients with seizure disorders requiring anticonvulsant therapy&#xD;
&#xD;
          9. Any of the following abnormal baseline hematologic/laboratory values:&#xD;
&#xD;
             Hb &lt; 10g/dl WBC &lt; 3.0x109 /l Platelets &lt; 100x109 /l&#xD;
&#xD;
         10. Presence of active autoimmune disease&#xD;
&#xD;
         11. Concurrent systemic glucocorticoids or any other systemic immunosuppressive therapy&#xD;
&#xD;
         12. Unwilling or unable to comply with the requirements of the protocol&#xD;
&#xD;
         13. Known infection with HBV, HCV, HIV&#xD;
&#xD;
         14. Pregnant or lactating women&#xD;
&#xD;
         15. Unwillingness or inability to employ an effective barrier method of birth control&#xD;
             throughout the study and for up to 3 months after end of treatment in female or male&#xD;
             patients&#xD;
&#xD;
         16. Known or suspected allergy to human interferon alpha or any ingredient of the IMP.&#xD;
&#xD;
         17. Any thyroid dysfunctions not responsive to therapy&#xD;
&#xD;
         18. Presence of chronic hepatitis with decompensated liver cirrhosis&#xD;
&#xD;
         19. Immunosuppression in patients with transplantation&#xD;
&#xD;
         20. Evidence or history of bleeding diathesis or coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätshautklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <last_update_submitted>November 11, 2014</last_update_submitted>
  <last_update_submitted_qc>November 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Benjamin Weide, M.D.</investigator_full_name>
    <investigator_title>Dr. Benjamin Weide</investigator_title>
  </responsible_party>
  <keyword>Malignatn Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

